Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 666
- Registration Number
- NCT01740427
- Locations
- 🇺🇸
Translational Research Management, Los Angeles, California, United States
🇺🇸UCLA West Medical Pharmacy: Drug Management Only, Los Angeles, California, United States
🇺🇸UCLA West Medical Pharmacy, Los Angeles, California, United States
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT01720602
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT01698918
- Locations
- 🇺🇸
Breastlink Medical Group Dept. of BreastlinkResearchGrp, Long Beach, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Alabama Comprehensive Cancer Center SC-2, Birmingham, Alabama, United States
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 53
- Registration Number
- NCT01686828
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT01684215
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 200
- Registration Number
- NCT01679574
- Locations
- 🇪🇬
Assiut University, Assiut, Egypt
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1939
- Registration Number
- NCT01674140
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Aria Health-Torresdale Campus, Philadelphia, Pennsylvania, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Aromatase Inhibitor Host Factors Study
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2021-05-13
- Target Recruit Count
- 121
- Registration Number
- NCT01669343
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Women's College Hospital, Toronto, Ontario, Canada
A Study of LY3023414 in Participants With Advanced Cancer
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT01655225
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy
Randomized Study of Letrozole and Trilostane for Medical Abortion
- Conditions
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Kristina Gemzell Danielsson
- Target Recruit Count
- 36
- Registration Number
- NCT01615211
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.